India’s pharmaceutical exports rose by 9.4% in 2024–25, reaching $30.47 billion, as per the Ministry of Commerce and Industry. The industry aims for double-digit growth in 2026–27, backed by strong government backing. The government’s focus on expanding India’s global presence in medicines was highlighted during an interaction themed “Scaling up Pharma Exports.”
The pharmaceutical sector in India, currently valued at $60 billion, is anticipated to reach $130 billion by 2030. India stands third globally in both medicine production volume and exports, shipping pharmaceuticals to over 200 countries. Notably, more than 60% of these exports are directed to highly regulated markets, with the U.S. accounting for 34% and Europe for 19% of India’s pharmaceutical exports.
The Commerce Secretary stressed the importance of consistent engagement with exporters and manufacturers to address challenges in regulated markets promptly. Emphasizing Prime Minister Narendra Modi’s vision, efforts are aimed at solidifying India’s position as a reliable global trade partner, ensuring the continued supply of affordable, high-quality medicines worldwide.
The inaugural session, attended by various entities including the Department of Commerce, DGFT, CDSCO, and industry representatives, focused on streamlining regulatory processes, enhancing export facilitation, and aligning policies with the sector’s growth trajectory. Special emphasis was placed on supporting Micro, Small, and Medium Enterprises (MSMEs) to overcome compliance, documentation, and inspection hurdles. Discussions also delved into the Union Budget 2026–27, highlighting the prioritization of biopharma and biologics in India’s healthcare and manufacturing landscape. The proposed Biopharma SHAKTI initiative, with a budget of Rs 10,000 crore over five years, aims to bolster India’s biologics ecosystem, reduce import reliance, and secure 5% of the global biopharmaceutical market.
